Q3 EPS Forecast for Agilent Technologies Lowered by Analyst

Agilent Technologies, Inc. (NYSE:A) – Stock analysts at Zacks Research reduced their Q3 2025 earnings estimates for Agilent Technologies in a research report issued on Thursday, June 12th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $1.36 per share for the quarter, down from their prior forecast of $1.39. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.58 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.59 EPS, Q1 2026 earnings at $1.42 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.50 EPS, Q1 2027 earnings at $1.64 EPS, Q2 2027 earnings at $1.63 EPS and FY2027 earnings at $6.57 EPS.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.05. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.63 billion. During the same quarter last year, the business posted $1.22 EPS. The company’s revenue was up 6.0% on a year-over-year basis.

Several other research firms have also commented on A. JPMorgan Chase & Co. lowered their price objective on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating on the stock in a research report on Thursday, May 29th. Leerink Partners boosted their target price on shares of Agilent Technologies to $135.00 and gave the company a “buy” rating in a research note on Friday, May 30th. UBS Group lowered their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a report on Thursday, May 29th. TD Cowen lifted their price objective on shares of Agilent Technologies to $150.00 and gave the company a “buy” rating in a report on Thursday, May 29th. Finally, Robert W. Baird decreased their price objective on shares of Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating for the company in a research report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Hold” and an average price target of $140.15.

Agilent Technologies Stock Down 1.6%

Shares of A stock opened at $116.97 on Monday. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $153.84. The stock has a market cap of $33.23 billion, a P/E ratio of 28.88, a P/E/G ratio of 3.55 and a beta of 1.23. The stock has a 50 day moving average of $109.34 and a 200 day moving average of $125.29. The company has a current ratio of 2.09, a quick ratio of 1.60 and a debt-to-equity ratio of 0.55.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 23rd. Stockholders of record on Tuesday, July 1st will be given a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.85%. Agilent Technologies’s dividend payout ratio (DPR) is 24.44%.

Insider Transactions at Agilent Technologies

In other news, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now directly owns 35,737 shares of the company’s stock, valued at $4,161,931.02. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in A. Flynn Zito Capital Management LLC boosted its stake in Agilent Technologies by 3.8% during the 4th quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company’s stock worth $251,000 after purchasing an additional 69 shares during the last quarter. IFP Advisors Inc raised its position in shares of Agilent Technologies by 17.7% in the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock valued at $62,000 after buying an additional 69 shares during the last quarter. Tiemann Investment Advisors LLC lifted its stake in shares of Agilent Technologies by 5.6% in the fourth quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company’s stock worth $191,000 after buying an additional 75 shares in the last quarter. Rothschild Investment LLC lifted its stake in shares of Agilent Technologies by 19.2% in the fourth quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock worth $66,000 after buying an additional 79 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in Agilent Technologies by 1.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company’s stock worth $1,025,000 after acquiring an additional 87 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.